stockrowEnovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- +100.6%
- Free cash flow
- +20.3%
- Total debt
- −7.45%
Quarter to September 2026, against a year earlier
Follow ENOV
Alert me
Enovis Corporation (ENOV) EV/Sales
As of 6 November 2026, Enovis Corporation (ENOV) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.7× (December 2015) to 20.9× (November 2021); the current reading is higher than 21% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | (29.68%) |
| FY2024 | 1.8× | (13.52%) |
| FY2023 | 2.0× | 0.09% |
| FY2022 | 2.0× | (65.74%) |
| FY2021 | 5.9× | (9.74%) |
| FY2020 | 6.6× | 206.27% |
| FY2019 | 2.1× | 29.47% |
| FY2018 | 1.7× | (42.22%) |
| FY2017 | 2.9× | 62.62% |
| FY2016 | 1.8× | 110.13% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.0× | (7.11%) |
| Jun 2026 | 1.1× | (5.85%) |
| Mar 2026 | 1.1× | (7.86%) |
| Dec 2025 | 1.2× | (9.74%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.2× |
| ENOV Enovis Corporation | 1.3× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.3× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| CNMD CONMED Corporation compare | 1.7× |
| NVCR NovoCure Limited compare | 1.8× |
| ATEC Alphatec Holdings, Inc. compare | 2.0× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.8× |
| AORT Artivion, Inc. compare | 3.2× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)